Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 107.97% | 116.63% | -42.75% | -70.81% | -66.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 107.97% | 116.63% | -42.75% | -70.81% | -66.36% |
| Cost of Revenue | 173.44% | 159.62% | -64.83% | -134.60% | -136.40% |
| Gross Profit | 39.69% | 34.29% | -39.08% | -47.41% | -36.92% |
| SG&A Expenses | -8.45% | 42.63% | 68.55% | 46.94% | 83.52% |
| Depreciation & Amortization | 21.40% | 35.93% | 62.40% | 76.79% | 63.40% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.15% | 65.97% | 57.65% | 22.36% | 35.57% |
| Operating Income | 19.59% | -51.85% | -236.93% | -327.43% | -400.43% |
| Income Before Tax | 14.80% | -52.52% | -155.94% | -188.86% | -207.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.80% | -52.52% | -155.94% | -188.86% | -207.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.80% | -52.52% | -155.94% | -188.86% | -207.82% |
| EBIT | 19.59% | -51.85% | -236.93% | -327.43% | -400.43% |
| EBITDA | 19.01% | -54.70% | -254.58% | -435.36% | -562.92% |
| EPS Basic | 23.29% | -33.03% | -129.41% | -157.89% | -175.47% |
| Normalized Basic EPS | 23.60% | -33.33% | -128.57% | -157.14% | -169.70% |
| EPS Diluted | 23.29% | -33.03% | -129.41% | -157.89% | -175.47% |
| Normalized Diluted EPS | 23.60% | -33.33% | -128.57% | -157.14% | -169.70% |
| Average Basic Shares Outstanding | 12.41% | 15.06% | 12.39% | 11.16% | 8.46% |
| Average Diluted Shares Outstanding | 12.41% | 15.06% | 11.78% | 10.55% | 7.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |